• Amel Belgacem, Neyla Ben Gdara, Ikram Khemiri, and Lotfi Bitri.
• Department of Biology, University of Tunis El Manar, Faculty of Sciences of Tunis, University campus 2092, El Manar, Tunis, Tunisia.
• Afr Health Sci. 2019 Dec 1; 19 (4): 2846-2853.

Background And ObjectivesA lot of research has been directed towards medicinal plants which are considered as a source of multiple phytotherapic substances endowed with hypoglycemic activities that could be used to treat diabetes and its complications. Our study was carried out in Wistar rats to investigate the hypoglycemic effect of n-Butanol Fraction from Artemisia campestris leaf Methanolic Extract (BFACME).MethodsTwo experimental models were used in rats: orally induced hyperglycemia (OGTT) and isolated perfused liver (IPRL).ResultsBFACME at 550 mg/kg BW dose significantly reduced fasting glucose level in normal rats as compared to controls. The decrease of glycaemia was 12.6% more significant than that obtained with the standard drug glibenclamide (10 mg/kg BW), an oral antidiabetic preparation belonging to sulfonylurea class. In OGTT model, BFACME at the highest doses of 550 and 400 mg/kg BW significantly reduced the postprandial hyperglycemic peak compared to controls. In the IPRL model, treatment with BFACME significantly decreased glucose concentrations after 30 min of perfusion with 30 mM glucose solely when insulin was present. The higher doses of BFACME lead to glucose concentration at basal level as early as 90 min, while the lowest dose does not restore this concentration even to t = 120min. The best initial glucose concentration retrieval was obtained with 0.7 mg BFACME/mL/g liver. At this dose, BFACME improves the decrease of glucose level caused by only insulin by about 18%.ConclusionThe BFACME appears to exert a hypoglycemic activity by potentiating the insulin action.© 2019 Belgacem et al.

21 keywords...

hide…